Open Access Library Journal

Volume 10, Issue 5 (May 2023)

ISSN Print: 2333-9705   ISSN Online: 2333-9721

Google-based Impact Factor: 0.73  Citations  

Vertigo and H4 Antagonist Effect on Vestibular Symptoms

HTML  XML Download Download as PDF (Size: 533KB)  PP. 1-21  
DOI: 10.4236/oalib.1110164    74 Downloads   726 Views  

ABSTRACT

Vertigo is a condition when a patient feels that the objects around him are moving, and this condition can lead to falls and serious incidences. Vertigo has various etiologies including central, peripheral, psychogenic, and medication-induced vertigo. The most common cause is benign paroxysmal positional vertigo (BPPV) then Meniere’s disease and labyrinthitis should be in the differential diagnosis. Ruling out serious conditions such as stroke is important. Various treatment options are used for vestibular symptoms and vestibular rehabilitation shows a positive result. Management of vertigo is the same for a long time despite the partial effect, unwanted side effects due to some drugs, and the need for multiple medications to relieve the symptoms in some patients. More effective treatment with lesser side effects needs to be used. Recently some in vivo trials come into view that H4 antagonist such as SENS-111 is effective in treating vestibular symptoms. These medications work by blocking the action of histamine, a chemical messenger involved in the immune response. More clinical trials and research need to be done on this type of treatment and other treatment options as this will lead to positive transformation in the future.

Share and Cite:

Saeed, L., Ali, H.E.M., Abdalla, Z.A.A., Elabbas, S.F., Eltayeb, M.E. and Mukhtar, W.M.M. (2023) Vertigo and H4 Antagonist Effect on Vestibular Symptoms. Open Access Library Journal, 10, 1-21. doi: 10.4236/oalib.1110164.

Cited by

No relevant information.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.